Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer

PURPOSE: Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone. To build on this strategy and fully integrate a repetitively dosed bone-seeking...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Morris, Michael J., Pandit-Taskar, Neeta, Carrasquillo, Jorge, Divgi, Chaitanya R., Slovin, Susan, Kelly, William K., Rathkopf, Dana, Gignac, Gretchen A., Solit, David, Schwartz, Lawrence, Stephenson, Ryan D., Hong, Christina, Delacruz, Anthony, Curley, Tracy, Heller, Glenn, Jia, Xiaoyu, O'Donoghue, Joseph, Larson, Steven, Scher, Howard I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684850/
https://ncbi.nlm.nih.gov/pubmed/19364960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.4164
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak